

**Research article: Myocardial Infarction; Early Prognostic Instrumental & Laboratory Markers: Single Cross-Sectional Analysis**

Running title: Advances in current cardiopathological management

**Authors' list: Basheer Abdullah Marzoog<sup>1,\*</sup>, Natalia Igorevna Bloshkina<sup>1</sup>, Vera Sergeevna Gromova<sup>2</sup>, Elena Ivanovna Gorshinina<sup>1</sup>**

<sup>1</sup> National Research Mordovia State University. Address: Bolshevitskaya Street, 68, Saransk, Rep. Mordovia, Russia. Postal address: Russia, Mordovia republic, Saransk, Bolshevitskaya Street, 31, 430005.

<sup>2</sup> Immanuel Kant Baltic Federal University, Russia, Kaliningrad, Alexander Nevsky Street, 14. ORCID 0000-0002-8707-8876

\*Corresponding author: Basheer Abdullah Marzoog, undergraduate medical school student at National Research Mordovia State University (marzug@mail.ru, +79969602820). Address: Bolshevitskaya Street, 68, Saransk, Rep. Mordovia, 430005. Postal address: Mordovia republic, Saransk, Bolshevitskaya Street, 31. ORCID: 0000-0001-5507-2413, Scopus ID: 57486338800

Competing interests: No competing interests regarding the publication.

All authors read and approved the final version of the manuscript

## Abstract

**Background:** Cardiovascular events remain one of the frequently reported causes of death globally.

**Aims:** Assess the early laboratory and instrumental changes in systemic manner.

**Objectives:** Patients with fresh myocardial infarction that has been occurred in less than 30 days before hospitalization in the rehabilitation hospital.

**Materials and methods:** A single large-scale retrospective cohort sectional study for patients with fresh myocardial infarction for the period 2014-2019, data collected from Mordovia Rehabilitation Hospital. The study involved 154 patients and analysed 76 parameters for each patient. The t test, Pearson's correlation coefficient, and ROC test have been used. For statistical analysis used Statistica program.

**Results:** The sample included 154 patients with a history of fresh myocardial infarction. Of 154. 51(33.11%) female and 103 (66.88 %) males. Chronic heart failure (CHF), which is seen in 42 (27.27273 %) patients, 101 (65.58442 %) did not have CHF and 11 (7.14286 %) missing data. Diabetes mellitus (DM) has been observed in 28 (18.18182 %), 118 (76.62338 %) without DM, Hypertension has been seen in 118 (76.62338 %), 28 (18.18182%) did not have hypertension, chronic kidney disease (CKD) has been seen in 11 (7.14%) patients, 131 (85.06494 %) did not have CKD, Chronic obstructive pulmonary disease (COPD) existed in 14 (9.09091%), 132 (85.71429 %) did not have COPD. Post myocardial infarction (MI) CHF has been seen in 108 (70.12987%), 42 (27.27273 %) did not have CHF. Post MI arrhythmia seen in 50 (32.47%) patients, 99 (64.28571%) did not have arrhythmia. Early post MI complication such as aneurysm has been seen in 12 (7.79221%), 138 (89.61039 %) did not have aneurysm, Dressler syndrome; pericarditis has been seen in 4 (2.59740%) patients, pneumonitis seen in 1 (0.64935%) patient, and pleuritis have not been seen.

**Conclusions:** Systemic manifestations include kidney function impairment or development of new kidney disease. These changes include an increase in the aorta basement diameter, an increase in the right ventricle size, a decrease in the level of serum red blood cells, the serum potassium level, and serum calcium level, with an increase in the serum myoglobin.

**Others:** Females are more frequently affected by post-MI urinary tract infection.

**Keywords:** Myocardial infarction, Cardiology, Myocardiopathies, Myocardiocyte, Angiogenesis, Regeneration

## Introduction

Myocardial infarction (MI) and associated sequelae remain the most reported cause of mortality and morbidity worldwide [1]. The development of cardiovascular events is associated with several modified and non-modified risk factors [2]. Lifestyle changes have a huge impact on the overall health of the cardiovascular system [3, 4]. Unfortunately, sedentary lifestyle is seen in majority of myocardial infarction, which is associated with development of several predisposition factors for cardiovascular events such as dyslipidaemia, insulin resistance, and central obesity or visceral obesity [5–7]. Collectively, these early signs of disturbance of cardiovascular homeostasis are ignored to provoke the progression of dyslipidaemia and insulin resistance to reach enough levels to induce the emergence of cardiovascular events such as MI [8, 9].

Assessment of the early post-MI changes is of huge impact on the further therapy plan and the prognosis of MI victims. One of the early specific markers of myocardial infarction is the elevation of cardiac lactate dehydrogenase 1 and troponins, including troponins I and T. However, systemic changes are rarely assessed in early post-MI patients [10]. The role of these changes is unclear in determining the prognosis of patients with MI and the potential risk of developing complications such as renal failure. In the current retrospective analysis, we covered the potential role of these systemic and the regularly checked cardiac markers in the prognosis determination and prognosis of the patients.

## Materials and methods

A retrospective cohort analysis for 155 patients for the period 2014–2019. The data has been collected from the republican rehabilitation hospital. Consent from patients has been taken for the collection, analysis, and publication the material and any associated photos or graphs. The missing data have been treated as absent and removed from the analysis. All measurement units are based on the local units used in the laboratories. There was no access to the 2020–2022 year data because of the COVID-19 issues. Pleuritis was not seen in patients and been excluded from the complications report. The presented t-test results are all statistically significant and other non-mentioned results are not statistically significant at  $p < 0.05$ . The level of leukocytes and red blood cell level is always mentioned without  $\times 10^9$  or  $\times 10^{12}$ , respectively. We could not assess the risk hazard for the estimated parameters and the survival rate, limitations of the study.

The T test, the Pearson correlation coefficient and ROC analysis have been used using the Statistica 12 programme (StatSoft, Inc. (2014). STATISTICA (data analysis software system), version 12. [www.statsoft.com](http://www.statsoft.com)).).

## Results

The sample included 154 patients with a history of fresh myocardial infarction. Of 154, 51 (33.11%) were female and 103 (66.88%) were male. In the sample, 131 (85.06494 %) live in the city, 17 (11.03896 %) live in the village, and 5 (3.24675%) live in the town.

Majority of the patient had a concomitant disease prior to their myocardial infarction. 132 (85.71429%) had a concomitant disease, 18 (11.68831%) did not have a concomitant disease, and 4 (2.59740 %) missing data. Of the concomitant diseases, chronic heart failure (CHF), which is seen in 42 (27.27273 %) patients, 101 (65.58442 %) did not have CHF, and 11 (7.14286 %) missing data. Diabetes mellitus (DM) has been observed in 28 (18.18182 %), 118 (76.62338 %) without DM, and 8 (5.19481 %) missing data. Hypertension has been seen in 118 (76.62338 %), 28 (18.18182%) did not have hypertension, and 8 (5.19481%) missing data. Chronic kidney disease (CKD) has been observed in 11 (7.14%) patients, 131 (85.06494 %) did not have CKD, and 12 (7.79221 %) were missing data. Chronic obstructive lung disease (COPD) existed in 14 (9.09091%), 132 (85.71429 %) did not have COPD and 8 (5.19481 %) missing data. A disrupted lipid profile was present in 21 (13.63636 %), 121 (78.57143 %) did not have dyslipidaemia and 12 (7.79221 %) missing data. Varicose vein is coexisted in 3 (1.94805%), 137 (88.96104%) did not have varicose vein, and 14 (9.09091%) missing data.

In terms of complications after myocardial infarction, 145 (94.15584 %) patients had complication, 5 (3.24675%) did not have complication, and 4 (2.59740%) had missing data. Post-myocardial infarction (MI) CHF has been observed in 108 (70.12987%), 42 (27.27273 %) did not have CHF, and 4 (2.59740 %) missing data. Post MI arrhythmia seen in 50 (32.47%) patients, 99 (64.28571%) did not have arrythmia, 5 (3.24675%) missing data. Early post MI complication such as aneurysm has been seen in 12 (7.79221%), 138 (89.61039 %) did not have aneurysm, and 4 (2.59740%) missing data. Late post MI complications including Dressler syndrome including the pericarditis has been seen in 4 (2.59740%) patients, 146 (94.80519%) did not have pericarditis, and 4 (2.59740 %) missing data. Additional components of Dressler syndrome include pneumonitis, which is seen in 1 (0.64935%) patient, 148 (96.10390%) did not have pneumonitis, and 5 (3.24675 %) missing data. Whereas, the third component of the Dressler syndrome, pleuritis, have not been seen, therefore, it has not been reported.

Interestingly, 43 (27.92208%) patients had re-infarct, 107 (69.48052 %) were for the first time, and 4 (2.59740 %) missing data. Evaluation of the activity level of tissue-type plasminogen activator (t-PA) through serum level, it was elevated in 7 (4.54545%) patients, 5

(3.24675%) in the normal range, and other 142 (92.20779%) did not measure their d-dimer level.

The primary descriptive statistics demonstrated in (*Table*) 1.

Table 1: The primary descriptive statistics of the sample. Abbreviations: EF; ejection fraction, EDV; end diastolic volume, LV; left ventricle, LA; left atrium, RV; right ventricle, RA; right atrium, Hb; hemoglobin, RBC; red blood cell, ESR; erythrocyte sedimentation rate of erythrocytes, CKP-MB; creatinine phosphokinase-MB fraction, LDH; lactate dehydrogenase, ALT; alanine transaminase, AST; aspartate transaminase, LDL; low density lipoprotein, TAG; triacyl glycerides, APTT; activated prothrombin time, PT; prothrombin time.

Variable	Descriptive Statistics					
	Valid N	% Valid obs.	Mean	Median	Minimum	Maximum
Hospitalization days	153	99.35065	14.53	15.000	0.0000	24
Age (years)	152	98.70130	61.64	62.500	30.0000	86
Body weight (Kg)	31	20.12987	82.26	85.000	62.0000	112
Height (cm)	31	20.12987	170.58	172.000	155.0000	185
BMI (Kg/m <sup>2</sup> )	31	20.12987	28.56	27.888	21.7993	41
HR (beat/min)	148	96.10390	79.82	78.000	53.0000	130
SBP (mmHg)	148	96.10390	139.57	140.000	60.0000	260
DBP (mmHg)	148	96.10390	84.05	80.000	40.0000	130
Aorta diameter at the Valsalva sinuses (mm)	144	93.50649	35.21	35.000	20.0000	46
EF (%)	142	92.20779	54.55	55.000	25.0000	80
EDV (ml)	113	73.37662	134.30	129.000	62.0000	234
End diastolic LV size (mm)	132	85.71429	52.35	51.150	10.0000	89
End diastolic LA size (mm)	133	86.36364	40.09	40.000	28.0000	62
End diastolic RV size (mm)	144	93.50649	26.75	26.250	5.0000	44
End diastolic RA size (mm)	130	84.41558	35.73	36.000	24.0000	49

Variable	Descriptive Statistics					
	Valid N	% Valid obs.	Mean	Median	Minimum	Maximum
Hb	143	92.85714	137.10	138.000	85.0000	170
Leukocytes (/L)	141	91.55844	8.82	8.300	2.8000	18
RBC (/L)	118	76.62338	5.12	4.505	2.6000	24
Lymphocytes (%)	130	84.41558	25.51	25.500	2.0000	54
Thrombocytes (/L)	111	72.07792	206.76	200.000	83.0000	506
ESR (mm/hr)	138	89.61039	19.04	15.500	2.0000	60
Urine ketones (mmol/l)	1	0.64935	0.50	0.500	0.5000	1
Urine proteins (mmol/l)	137	88.96104	5.27	0.000	0.0000	150
Urine leukocytes (microscopically)	142	92.20779	2.64	1.000	0.0000	50
Urine epithelial cells (microscopically)	136	88.31169	1.86	1.000	0.0000	20
Troponin I (ng/ml)	126	81.81818	4.74	1.205	0.0000	33
Myoglobulin (ng/ml)	3	1.94805	111.30	71.000	63.0000	200
CKP-MB 1 (U/l)	129	83.76623	97.01	29.000	6.0000	2881
CKP-MB 2 (U/l)	71	46.10390	79.26	42.000	6.0000	508
LDH 1 (U/l)	108	70.12987	652.30	475.500	30.0000	3900
LDH 2 (U/l)	56	36.36364	21640.80	492.000	97.0000	1177
INR (Sec)	125	81.16883	1.25	1.000	0.8000	18
Total bilirubin (mmol/l)	108	70.12987	16.53	17.680	4.4200	36
ALT (mmol/l)	140	90.90909	42.65	28.000	1.1900	361
AST (mmol/l)	140	90.90909	55.57	30.000	5.1000	423
Total cholesterol (mmol/l)	141	91.55844	5.23	5.100	2.4000	9
LDL (mmol/l)	138	89.61039	23.20	3.240	0.9200	2766
TAG (mmol/l)	140	90.90909	3.65	1.565	0.2700	138
Na (mmol/l)	122	79.22078	139.76	142.750	1.7600	151

Variable	Descriptive Statistics					
	Valid N	% Valid obs.	Mean	Median	Minimum	Maximum
K (mmol/l)	126	81.81818	6.02	4.060	1.0000	92
Creatinine ( $\mu$ mol/L)	142	92.20779	81.56	84.000	0.0000	176
Ca (mmol/l)	115	74.67532	1.69	1.180	0.2500	38
Urea (mmol/l)	139	90.25974	7.79	6.700	2.5000	93
Glucose (mmol/l)	135	87.66234	6.86	6.100	4.0000	19
APTT (Sec)	74	48.05195	27.31	25.500	15.0000	76
Fibrinogen (ng/ml)	117	75.97403	3386.85	3500.000	300.0000	7500
PT (Sec)	1	0.64935	94.00	94.000	94.0000	94

Males are affected by myocardial infarction earlier compared to females; the cut-off point of age is 67 years old. (*Figure 1*)

In male group the mean age is 59.76 years old and in female group the mean age is 65.46 years old, which is statistically significant difference, t value 3.30972, p<0.001170. Furthermore, the mean height of the male is 172.57 cm and in female 164.88 cm, which is a statistically significant difference, t value -3.26225, p< 0.002829. On echocardiogram, in male group, the mean diameter of the aorta is 36.23 mm, in female group, the mean diameter of the aorta is 33.04 mm, which is statistically significant difference, t value -4.24952, p<0.000039. In male group, the mean right atrium size on echocardiogram equal to 36.26 mm, in female group equal to 34.56 mm, which is statistically significant difference, t value -2.06826, p< 0.040630. The mean hemoglobin level in men was 140.26 and in women 130.66, which is a statistically significant difference, t value -3.71265, p<0.000295. In urine analysis, in male group, mean number of leukocytes in urine was 1.52 under microscope and in female group was 4.91, which is statistically significant difference, t value 3.11688, p< 0.002218. Furthermore, in urine analysis, the number of epithelial cells in the male 1.36 under microscope and in the female group 2.91, which is a statistically significant difference, t value 3.12012, p< 0.002214. In the male group, the mean myoglobin level was 67.00 ng/ml and in the female group 199.90 ng/ml, which is a statistically significant difference, t value 19.18246, p< 0.033158.

Patients with concomitant diseases have a mean heart rate (HR) equal to 80.82 beats / minute and patients without concomitant disease have a mean HR equal to 72.39 beats / minute, which is a statistically significant difference, t value 2.05541, p< 0.041633. Furthermore,

patients with concomitant diseases have a mean diastolic size of the right ventricle is 27.13 mm and patients without concomitant disease have a mean diastolic size of the right ventricle is 23.85 mm, which is a statistically significant difference, t value 2.79969, p< 0.005833. Moreover, patients with concomitant disease have a mean protein in urine 3.18 mg/l, and the patients without concomitant disease had a mean level of urine protein 21.25 mg/l, which is statistically significant difference, t value -3.10080, p< 0.002353. Interestingly, patients with concomitant disease had lower calcium level a mean equal to 1.31 mmol/l and the patients without concomitant disease had a mean calcium level 3.84 mmol/l, which is statistically significant difference, t value -2.67394, p< 0.008608. (*Figure 2*)

Patients with CHF have a mean thrombocyte level equal to 185.26 / l, while patients without CHF have a mean thrombocyte level of 216.24 /l, which is a statistically significant difference, t value - 2.15343, p< 0.033573.

Mean glucose level in diabetic patients equal to 9.93 mmol/l and in non-diabetic patients equal to 6.13 mmol/l, which is statistically significant difference, t value -7.9724, p< 0.0001. The coexistence of DM in patients increases the mean diastolic size of the left ventricle 55.60 mm, while, in patients without DM, the mean diastolic size of the left ventricle to equal 51.42 mm, which is a statistically significant difference, t value -2.5388, p< 0.012341. The mean sedimentation rate (ESR) in patients with DM equals 23.60 mm/hr, and equal to 17.43 mm/hr in non-diabetic patients, which is statistically significant difference, t value -2.2236, p< 0.027887. The mean creatinine phosphokinase-MB fraction is dramatically higher in patients with DM 233.36 U/L and lower in non-diabetic patients 66.05 U / L, which is a statistically significant difference, t value --2.6267, p< 0.009726. Diabetic patients experience a high level of triacyl glyceride (TAG) 2.17 mmol / l, while non-diabetic patients had a lower TAG level of 1.66 mmol/l, which is a statistically significant difference, t value -2.5633, p< 0.011481.

Hypertensive patients have a low mean level of red blood cells (RBC) level 4.55 /l in compare to non-hypertensive patients 7.7, which is statistically significant difference, t value -4.63276, p< 0.000010. In hypertensive patients, the mean LDH 1 is 608.21 U/l, INR is 1.05, sodium is 141.70 mmo/l, potassium is 4.04 mmol/l, and calcium is 1.14 mmol/l, whereas, in non-hypertensive patients, the mean level of LDH 1 is 908.8 U/l, INR is 2.1, sodium is 130.6 mmol/l, potassium is 14.8 mmol/l, calcium is 3.9 mmol/l, which is statistically significant difference; t value -2.07903, -3.04226, 2.51546, -3.62102, -3.19601; p< 0.040123, 0.002890, 0.013268, 0.000432, 0.001828, respectively.

CKD patients have a high mean troponin I level equal to 22.70 ng / ml compared to non-CKD patients 3.72 ng/ml, which is a statistically significant difference, t value -6.84999, p< 0.0001. Also, CKD patients have higher mean level of CPK-MB fraction equal to 475.61 U/l in compare to non-CKD patients equal to 78.38 U/l, which is statistically significant difference, t value -3.63297, p< 0.000415. The mean creatinine level is higher in patients with CKD at 109.81  $\mu$ mol/L comparing to non-CKD patients, which is a statistically significant difference, t value -3.63297, p< 0.000415.

Interestingly, patients with COPD have a mean diastolic size of the left ventricle is 48.46 mm, which is less than those of patients 52.73 mm, which is a statistically significant difference, t value 1.99093, p< 0.048653. However, patients with COPD have a mean diastolic size of the right atrium is 39.55 mm compared to patients 35.41 mm, which is a statistically significant difference, t value -3.06986, p< 0.002632. Furthermore, COPD patients have a mean level of RBC equal to 145.29 compared to non-COPD patients 136.39, which is a statistically significant difference, t value -2.11854, p< 0.035948.

Patients with dyslipidemia have mean troponin I 9.4 ng/ml, whereas, patients without dyslipidemia have mean troponin I 3.64 ng/ml, which is statistically significant difference, t value -2.99785, p< 0.003316. Additionally, patients with dyslipidaemia have mean total bilirubin 19.3 mmol / l and 15.72 mmol/l in patients without dyslipidaemia, which is a statistically significant difference, t value -2.12114, p< 0.036358. Furthermore, patients with dyslipidaemia have a mean serum sodium level of 132.3 mmol/l and a mean serum potassium level of 8.4 mmol / l, while in patients without dyslipidaemia, the mean sodium serum level is 142.24 mmol/l and a mean serum potassium level of 4.07 mmol/l, which is a statistically significant difference; t value 2.74875, -2.09792; p< 0.006966, 0.038083.

The mean leukocytes level in patients with varicose veins is 12.07 /l, whereas, in patients without varicose veins, the mean leukocytes level is 8.71 /l, which is statistically significant difference; t value -1.99832, p< 0.047801. The mean RBC level in patients with varicose veins is 9.87 /l, whereas, in patients without varicose veins, the mean RBC level is 4.56 /l, which is statistically significant difference; t value -6.88122, p< 0.000000. The mean level of ESR in patients with varicose veins is 37.67 mm / h, while, in patients without varicose veins, the mean ESR level is 18.25 mm / h, which is statistically significant difference; t value -2.64654, p< 0.009161.

In terms of complications, patients with complications have been hospitalized for 14.65 days, whereas, patients without complications hospitalized for 11.40 days, which is statistically significant difference; t value 2.05492, p< 0.041657. In patients with complications, the

mean aorta diameter 35.38 mm, whereas, in patients without complications, the mean aorta diameter 29.25 mm, which is statistically significant difference; t value 2.77454, p< 0.006278. In patients with complications, the mean diastolic size is of the right ventricle is 26.89 mm, while, in patients without complications, the mean diastolic size of the right ventricle 21.25mm, which is a statistically significant difference; t 2.44283, p< 0.015809. In patients with complications, the mean level of RBC 4.87 / l, while in patients without complications, the mean level of RBC 12.40 /l, which is a statistically significant difference; t value -5.37900, p< 0.0001. In patients with complications, in the general urine analysis, microscopically, the mean level of urea proteins 4.30, while, in patients without complications, the mean level of urea proteins 50.00, which is a statistically significant difference; t -3.61867, p< 0.000419. In patients with complications, the mean potassium level 5.37 mmol/l and mean calcium level 1.58 mmol/l, whereas, in patients without complications, the mean potassium level 32.99 mmol/l and mean calcium level is 5.99 mmol/l, which is statistically significant difference; t value -3.75574, -2.05930; p< 0.000265, 0.041784, respectively.

Patients with post-MI CHF have mean myoglobin level 199.90 ng/ml, whereas, in patients without post-MI CHF, the mean myoglobin level 67.00ng/ml, which is statistically significant difference; t value 19.18246, p< 0.033158.

Patients with a history of previous infarction have creatinine 90.48  $\mu$ mol/l in compare to patients without reinfarction 78.01  $\mu$ mol/l, which is a statistically significant difference; t value 2.26506, p< 0.025056.

The mean age of patients with arrhythmia is 65.58 years, while the mean age of patients without arrhythmia is 59.68 years, which is statistically significant difference; t value 3.32256, p< 0.001129. The mean height of patients with arrhythmia is 173.67 cm, while the mean height of patients without arrhythmia is 168.61 cm, which is statistically significant difference; t value 2.23386, p< 0.034675. The mean ejection fraction (EF) of patients with arrhythmia is 50.40 %, while the mean EF of patients without arrhythmia is 56.43 %, which is statistically significant difference; t -3.81906, p< 0.000202. The mean diastolic size of the left atrium of patients with arrhythmia is 42.14 mm, while the mean diastolic size of the left atrium of patients without arrhythmia is a 39.12 mm, which is statistically significant difference; t 3.00570, p< 0.003189. The mean diastolic size right atrium of patients with arrhythmia is 37.36 mm, whereas, the mean diastolic size of the right atrium of patients without arrhythmia is 34.95 mm, which is statistically significant difference; t value 2.96567, p< 0.003614. The mean CKP-MB of patients with arrhythmia is 181.82 U / l, while the mean CKP-MB of

patients without arrhythmia is 56.68 U/l, which is statistically significant difference; t 2.34423, p< 0.020643. The mean serum lactate dehydrogenase (LDH) level of patients with arrhythmia is 888.37 U/l, whereas, the mean lactate dehydrogenase level of patients without arrhythmia is a 533.49 U/l, which is statistically significant difference; t value 3.16430, p< 0.002039. The mean serum level of aspartate transaminase of patients with arrhythmia is 71.53 mmol / l, while the mean lactate dehydrogenase serum level of patients without arrhythmia is a 47.38 mmol/l, which is statistically significant difference; t value 2.23750, p< 0.026893.

The mean EF of patients with aneurysm is 43.00 %, whereas, the mean EF of patients without aneurysm is 55.59 %, which is statistically significant difference; t value 4.57958, p< 0.000010. The mean level in patients with aneurysm is 9.70 / l, while the mean leukocyte level of patients without aneurysm is 2.11 /l, which is statistically significant difference; t - 3.83162, p< 0.000192. The mean epithelial cell level in general urine analysis in patients with aneurysm is 5.40, whereas, the mean epithelial cell level in patients without aneurysm is 1.58, which is statistically significant difference; t value -4.41313, p< 0.000021.

The mean diastolic size of the left atrium of patients with pericarditis is 45.5 mm, while the mean diastolic size of the left atrium of patients without pericarditis is 39.90 mm, which is statistically significant difference; t value -2.01849, p< 0.045598. The mean creatinine level of patients with pericarditis is 52.5  $\mu$ mol/L, whereas, the mean creatinine level of patients without pericarditis is 82.39  $\mu$ mol/L, which is statistically significant difference; t value 1.98986, p< 0.048568.

Patients with pneumonitis have mean aorta diameter of 20.00 mm, whereas, the mean aorta diameter of patients without pneumonitis is 35.32 mm, which is statistically significant difference; t value 3.55083, p< 0.000524. Patients with pneumonitis have mean serum leukocytes level of 14.80 /l, whereas, the mean serum leukocytes level of patients without pneumonitis is 8.70 /l, which is statistically significant difference; t value -2.11170, p< 0.036527. Patients with pneumonitis have a mean ESR level of 48.00 mm / hour, while the mean ESR level of patients without pneumonitis is an 18.47 mm/he, which is statistically significant difference; t value -2.36894, p< 0.019267. Furthermore, patients with pneumonitis have a mean leukocyte level of 22.00, whereas, the mean urine leukocyte level in urine of patients without pneumonitis is a 2.53, which is statistically significant difference; t value - 3.15623, p< 0.001963. The mean CKP-MB in patients with pneumonitis is 1164.00 U / l, while the mean CKP-MB in patients without pneumonitis is 89.60 U/l, which is statistically significant difference; t -3.92161, p< 0.000144.

The mean diameter of the aorta, EF, EDV, troponin I, CKP-MB, and APTT in patients with elevated troponin T is 28.00 mm, 36.00 %, 62.00 ml, 33.00 ng/ml, 2881.00 U / l, and 49.10 s, respectively. Whereas, the mean aorta diameter, EF, EDV, troponin I, CKP-MB, APTT in patients without elevation in troponin T is 35.31 mm, 54.68%, 134.95 ml, 4.51 ng/ml, 75.26 U/l, 27.01 sec, respectively, which is statistically significant difference; t value 2.3478, 2.0136, 2.0775, -3.6144, -19.3413, -2.5572, p< 0.020266, 0.045967, 0.040063, 0.000436, 0.000000, 0.012661, respectively.

The mean age of patients with an elevated level is 68.14 years, and the mean age of patients with normal D is 56.60 years, which is statistically significant difference; t value 2.25820, p< 0.047513. The mean diastolic size of the right ventricle of patients with elevated D-dimer level is 25.93 mm, and mean diastolic size of the right ventricle of patients with normal D-dimer is 29.40 mm, which is statistically significant difference; t value -2.35428, p< 0.040345.

Comparing the dependent variable shows no statistical differences. (*Figure 3*)

In terms of correlations, a full table shows the correlation between all the continuous variables is presented. (*Table 2*)

An interesting correlation between the level of LDL and the diameter of the aorta basement has been observed. (*Figure 4*) It has been shown that when the diastolic size of the left ventricle increases, the EF decreases dramatically. (*Figure 4*)

## Discussion

Post-MI changes include early and late pathophysiological changes, early post-MI complications include ventricular rupture, aneurism, arrhythmia, sudden cardiac arrest, and death [11–13]. However, late changes include pericarditis, pneumonitis, pleuritis, and post-infarction cardiosclerosis and dyskinesia [14, 15]. Such manifestations are associated with some laboratory and instrumental changes. Assessment of these changes helps prevent or slow down or at least make a prognosis for patients with MI. The low level of thrombocytes in patients with concomitant CHF returns to the use of antiaggregant and anticoagulants for a long time.

The high level of leukocytes in diabetic patients endorses the hypothesis of a mild chronic mild inflammatory syndrome in patients with metabolic syndrome [16–19]. The high TAG values in diabetic patients are due to lipogenesis from high glucose serum levels and metabolic disorders associated with chronic lipid peroxidation and biogenesis disorders [16, 20]. The dramatic increase in diastolic size in of the right ventricle patients with COPD is an indicator of the stable stage of pulmonary heart, which is associated with pulmonary

hypertension and blood stagnation in the pulmonary circulation [21, 22]. Typically, these patients experience coughing and shortness of breath in the background of distress syndrome, fluid accumulation in pulmonary tissue, and impaired ability of pneumocytes to exchange gas. As compensation for respiratory hypoxemia, the elevation of the levels of erythropoietin and the further elevation of erythropoiesis, which is demonstrated in the high level of Hb in patients with COPD.

Leukocytosis is seen in patients with varicose veins and is an indicator of persistent inflammation with an increase in tissue hypoxia and a further increase in the hypoxia inducer factor to stimulate erythropoietin production and an additional increase in the RBC level of red blood cells in patients with varicose veins [23, 24]. This persistent inflammation is confirmed by the elevation of the ESR level in patients with varicose veins [25–28].

Post-MI complications reported in 4/5 of the sample and these complications associated with some laboratory and instrumental changes. Suggesting that post MI laboratory changes are not limited to the local myocardial infarction changes to involves systemic manifestations such as kidney function impairment or development of new kidney disease. These changes include an increase in the aorta diameter at the basement level, an increase in the right ventricle wall, a decrease in the level of RBC, the serum potassium level, and serum calcium level, with an increase in the serum myoglobin.

Re-infarct worsens the kidney function and induces renal failure [29–32]. Aging is a risk factor for MI and arrhythmia development. Arrhythmia increases CPK-MB, LDH, AST, diastolic size of both atriums, and decreases EF. The higher the troponin level, the lower the EF and the fewer further sequelae.

An early post-MI aneurysm significantly alters cardiac output and further reduces systemic systolic blood pressure. These changes are associated with the reduction in the blood flow in to the renal afferent fibers, which are sensed by the juxtaglomerular apparatus that leads to activation the renin angiotensin aldosterone system with the anti-diuretic hormone. Therefore, a reduction in kidney function is observed in patients with MI. Additionally, elevation of creatinine in aneurysm patients is typical for impaired kidney function particularly filtration due to hypoperfusion of the glomeruli.

Patients with pneumonitis are having a high leukocyte in serum and in the urine, high ESR, and high CKP-MB fraction. However, these patients experience small diameter of the aorta basement.

## **Conclusions**

The early prognostic value of the instrumental and laboratory changes is complication dependent. With age, the level of D-dimer and thrombocytes increases. The higher the troponin level, the lower the EF and the fewer further sequelae. Systemic manifestations include kidney function impairment or development of new kidney disease. These changes include an increase in the aorta diameter at the basement level, an increase in the right ventricle wall, a decrease in the level of serum red blood cells, the serum potassium level, and serum calcium level, with an increase in the serum myoglobin.

## **List of abbreviations**

CHF; chronic heart failure, DM; Diabetes mellitus, CKD; Chronic kidney disease, COPD; Chronic obstructive pulmonary disease, MI; myocardial infarction, HR; heart rate, ESR; erythrocytes sedimentation rate, RBC; red blood cells

## **Declarations**

### **ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

The study approved by the National Research Mordovia State University<sup>6</sup> Russia, from “Ethics Committee Requirement N8/2 from 30.06.2022”.

### **HUMAN AND ANIMAL RIGHTS**

No animals were used in this research. All human research procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2013.

### **CONSENT FOR PUBLICATION**

Written informed consent was obtained from the participants for publication of study results and any accompanying images.

### **AVAILABILITY OF DATA AND MATERIALS**

Not applicable.

### **FUNDING**

None.

### **CONFLICT OF INTEREST**

The authors declare no conflict of interest, financial or otherwise.

## ACKNOWLEDGEMENTS

Declared none.

## AUTHORS' CONTRIBUTIONS

MB collected the data from the hospital, inserted them into the excel file, analyzed the statistical data, wrote the draft, and revised the final version of the paper. NB, and VG inserted data into the excel file. EG gave me access to the rehabilitation hospital to collect the data. All authors have read and approved the manuscript.

## References

- [1] Tsao, C. W.; Aday, A. W.; Almarzooq, Z. I.; Anderson, C. A. M.; Arora, P.; Avery, C. L.; Baker-Smith, C. M.; Beaton, A. Z.; Boehme, A. K.; Buxton, A. E.; et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation*, **2023**. <https://doi.org/10.1161/CIR.0000000000001123>.
- [2] Yusuf, S.; Joseph, P.; Rangarajan, S.; Islam, S.; Mente, A.; Hystad, P.; Brauer, M.; Kutty, V. R.; Gupta, R.; Wielgosz, A.; et al. Modifiable Risk Factors, Cardiovascular Disease and Mortality in 155,722 Individuals from 21 High-, Middle-, and Low-Income Countries. *Lancet (London, England)*, **2020**, 395 (10226), 795. [https://doi.org/10.1016/S0140-6736\(19\)32008-2](https://doi.org/10.1016/S0140-6736(19)32008-2).
- [3] Ward, Z. J.; Bleich, S. N.; Cradock, A. L.; Barrett, J. L.; Giles, C. M.; Flax, C.; Long, M. W.; Gortmaker, S. L. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *N. Engl. J. Med.*, **2019**, 381 (25), 2440–2450. <https://doi.org/10.1056/NEJMSA1909301>.
- [4] Grundy, S. M. A Changing Paradigm for Prevention of Cardiovascular Disease: Emergence of the Metabolic Syndrome as a Multiplex Risk Factor. *Eur. Hear. J. Suppl.*, **2008**, 10 (suppl\_B), B16–B23. <https://doi.org/10.1093/EURHEARTJ/SUM044>.
- [5] Abdullah Marzoog, B. Adaptive and Compensatory Mechanisms of the Cardiovascular System and Disease Risk Factors in Young Males and Females. *New Emirates Med. J.*, **2022**, 04. <https://doi.org/10.2174/04666221128110145>.
- [6] Bays, H. E.; Taub, P. R.; Epstein, E.; Michos, E. D.; Ferraro, R. A.; Bailey, A. L.; Kelli, H. M.; Ferdinand, K. C.; Echols, M. R.; Weintraub, H.; et al. Ten Things to Know about Ten Cardiovascular Disease Risk Factors. *Am. J. Prev. Cardiol.*, **2021**, 5,

100149. <https://doi.org/10.1016/J.AJPC.2021.100149>.
- [7] Powell-Wiley, T. M.; Poirier, P.; Burke, L. E.; Després, J. P.; Gordon-Larsen, P.; Lavie, C. J.; Lear, S. A.; Ndumele, C. E.; Neeland, I. J.; Sanders, P.; et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*, **2021**, 143 (21), e984. <https://doi.org/10.1161/CIR.00000000000000973>.
- [8] Tian, X.; Chen, S.; Wang, P.; Xu, Q.; Zhang, Y.; Luo, Y.; Wu, S.; Wang, A. Insulin Resistance Mediates Obesity-Related Risk of Cardiovascular Disease: A Prospective Cohort Study. *Cardiovasc. Diabetol.*, **2022**, 21 (1). <https://doi.org/10.1186/S12933-022-01729-9>.
- [9] Lavie, C. J.; Ozemek, C.; Carbone, S.; Katzmarzyk, P. T.; Blair, S. N. Sedentary Behavior, Exercise, and Cardiovascular Health. *Circ. Res.*, **2019**, 124 (5), 799–815. <https://doi.org/10.1161/CIRCRESAHA.118.312669>.
- [10] Lorber, D. Importance of Cardiovascular Disease Risk Management in Patients with Type 2 Diabetes Mellitus. *Diabetes, Metab. Syndr. Obes.*, **2014**, 7, 169–183. <https://doi.org/10.2147/DMSO.S61438>.
- [11] Damluji, A. A.; Van Diepen, S.; Katz, J. N.; Menon, V.; Tamis-Holland, J. E.; Bakitas, M.; Cohen, M. G.; Balsam, L. B.; Chikwe, J. Mechanical Complications of Acute Myocardial Infarction: A Scientific Statement From the American Heart Association. *Circulation*, **2021**, 144 (2), E16–E35. <https://doi.org/10.1161/CIR.00000000000000985>.
- [12] Konstam, M. A.; Kramer, D. G.; Patel, A. R.; Maron, M. S.; Udelson, J. E. Left Ventricular Remodeling in Heart Failure: Current Concepts in Clinical Significance and Assessment. *JACC Cardiovasc. Imaging*, **2011**, 4 (1), 98–108. <https://doi.org/10.1016/J.JCMG.2010.10.008>.
- [13] Ibanez, B.; James, S.; Agewall, S.; Antunes, M. J.; Bucciarelli-Ducci, C.; Bueno, H.; Caforio, A. L. P.; Crea, F.; Goudevenos, J. A.; Halvorsen, S.; et al. 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation. *Eur. Heart J.*, **2018**, 39 (2), 119–177. <https://doi.org/10.1093/EURHEARTJ/EHX393>.
- [14] Marzoog, B. A.; Alexandrovich, K. O.; Nikolaevich, T. M.; Vladimirovich, K. S. Post-Coronary Artery Bypass Graft Complications; Potential Causes and Risk Factors. *medRxiv*, **2023**, 2022.12.29.22284005. <https://doi.org/10.1101/2022.12.29.22284005>.
- [15] Elbadawi, A.; Elgendi, I. Y.; Mahmoud, K.; Barakat, A. F.; Mentias, A.; Mohamed, A. H.; Ogunbayo, G. O.; Megaly, M.; Saad, M.; Omer, M. A.; et al. Temporal Trends and Outcomes of Mechanical Complications in Patients With Acute Myocardial

- Infarction. *JACC Cardiovasc. Interv.*, **2019**, 12 (18), 1825–1836.  
<https://doi.org/10.1016/J.JCIN.2019.04.039>.
- [16] Marzoog, B. Lipid Behavior in Metabolic Syndrome Pathophysiology. *Curr. Diabetes Rev.*, **2022**, 18 (6), e150921196497.  
<https://doi.org/10.2174/1573399817666210915101321>.
- [17] Marzoog, B. A. Tree of Life; Endothelial Cell Physiopathology, the Good Guy Is a Partner in Crime! *Anat. Cell Biol.*, **2023**.
- [18] Marzoog, B. A.; Vlasova, T. I. Beta-Cell Autophagy under the Scope of Hypoglycemic Drugs; Possible Mechanism as a Novel Therapeutic Target. *Obe. Metab.*, **2022**, 18 (4), 465–470. <https://doi.org/10.14341/omet12778>.
- [19] Marzoog, B. A. The Metabolic Syndrome Puzzles; Possible Pathogenesis and Management. *Curr. Diabetes Rev.*, **2022**, 18.  
<https://doi.org/10.2174/1573399818666220429100411>.
- [20] Glowinski, J.; Glowinski, S. Generation of Reactive Oxygen Metabolites by the Varicose Vein Wall. *Eur. J. Vasc. Endovasc. Surg.*, **2002**, 23 (6), 550–555.  
<https://doi.org/10.1053/EJVS.2002.1656>.
- [21] Marzoog, B. A. Pulmonary Fibrosis; Risk Factors and Molecular Triggers, Insight for Neo Therapeutic Approach. *Curr. Respir. Med. Rev.*, **2022**, 18 (4), 257–264.  
<https://doi.org/10.2174/1573398X18666220806124019>.
- [22] Marzoog, B. A. Local Lung Fibroblast Autophagy in the Context of Lung Fibrosis Pathogenesis. *Curr. Respir. Med. Rev.*, **2023**, 19 (1), 6–11.  
<https://doi.org/10.2174/1573398X19666221130141600>.
- [23] Poredos, P.; Spirkoska, A.; Rucigaj, T.; Fareed, J.; Jezovnik, M. K. Do Blood Constituents in Varicose Veins Differ From the Systemic Blood Constituents? **2015**.  
<https://doi.org/10.1016/j.ejvs.2015.04.031>.
- [24] Lattimer, C. R.; Kalodiki, E.; Geroulakos, G.; Hoppensteadt, D.; Fareed, J. Are Inflammatory Biomarkers Increased in Varicose Vein Blood? *Clin. Appl. Thromb.*, **2016**, 22 (7), 656–664.  
[https://doi.org/10.1177/1076029616645330/ASSET/IMAGES/LARGE/10.1177\\_1076029616645330-FIG2.JPG](https://doi.org/10.1177/1076029616645330/ASSET/IMAGES/LARGE/10.1177_1076029616645330-FIG2.JPG).
- [25] Bontekoe, E.; Brailovsky, Y.; Hoppensteadt, D.; Bontekoe, J.; Siddiqui, F.; Newman, J.; Iqbal, O.; Reed, T.; Fareed, J.; Darki, A. Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling. *Clin. Appl. Thromb.*, **2021**, 27. <https://doi.org/10.1177/10760296211013107>.

- [26] Dzieciuchowicz, L.; Espinosa, G.; Páramo, J. A. Increased Levels of Metalloproteinase 10 and Hemostatic Markers in Patients with Noncomplicated Primary Varicose Veins. *Clin. Appl. Thromb.*, **2015**, 21 (7), 684–687. <https://doi.org/10.1177/1076029613517167>.
- [27] Gwozdzinski, L.; Pieniazek, A.; Bernasinska-Słomczewska, J.; Hikisz, P.; Gwozdzinski, K. Alterations in the Plasma and Red Blood Cell Properties in Patients with Varicose Vein: A Pilot Study. *Cardiol. Res. Pract.*, **2021**, 2021. <https://doi.org/10.1155/2021/5569961>.
- [28] Jezovnik, M. K.; Fareed, J.; Poredos, P. Patients with a History of Idiopathic Deep Venous Thrombosis Have Long-Term Increased Levels of Inflammatory Markers and Markers of Endothelial Damage. *Clin. Appl. Thromb.*, **2017**, 23 (2), 124–131. <https://doi.org/10.1177/1076029616670259>.
- [29] Wang, C.; Pei, Y. Y.; Ma, Y. H.; Ma, X. L.; Liu, Z. W.; Zhu, J. H.; Li, C. S. Risk Factors for Acute Kidney Injury in Patients with Acute Myocardial Infarction. *Chin. Med. J. (Engl.)*, **2019**, 132 (14), 1660. <https://doi.org/10.1097/CM9.0000000000000293>.
- [30] Shacham, Y.; Leshem-Rubinow, E.; Steinvil, A.; Assa, E. Ben; Keren, G.; Roth, A.; Arbel, Y. Renal Impairment According to Acute Kidney Injury Network Criteria among ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Intervention: A Retrospective Observational Study. *Clin. Res. Cardiol.*, **2014**, 103 (7), 525–532. <https://doi.org/10.1007/S00392-014-0680-8>.
- [31] Tsai, T. T.; Patel, U. D.; Chang, T. I.; Kennedy, K. F.; Masoudi, F. A.; Matheny, M. E.; Kosiborod, M.; Amin, A. P.; Messenger, J. C.; Rumsfeld, J. S.; et al. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights from the NCDR Cath-PCI Registry. *JACC Cardiovasc. Interv.*, **2014**, 7 (1), 1–9. <https://doi.org/10.1016/J.JCIN.2013.06.016>.
- [32] Maksimczuk, J.; Galas, A.; Krzesiński, P. What Promotes Acute Kidney Injury in Patients with Myocardial Infarction and Multivessel Coronary Artery Disease—Contrast Media, Hydration Status or Something Else? *Nutr.* **2023**, Vol. 15, Page 21, **2022**, 15 (1), 21. <https://doi.org/10.3390/NU15010021>.

## Figure legend




Figure 1: Cut-off point for the age of the patients divided into male and female. Males are less than 67 years old. However, the female affected at more than 67 years of age.




Figure 2: Diagramed presentation of the concomitant and the post MI compilations. From below complications (CHF, DM, hypertension, CKD, COPD, dyslipidaemia, varicose veins) belong to concomitant diseases before the development of MI. Abbreviations: CHF; chronic heart failure, COPD; chronic obstructive pulmonary disease, CKD; chronic kidney disease, DM; diabetes mellitus.




Figure 3: Graphical presentation of the dynamical changes in the levels of LDH (lactate dehydrogenase) and CPK-MB (creatinine phosphokinase-MB fraction). Both LDH and CPK-

MB fraction measured by U/L. this analysis conducted between two days for all patients as a follow up after MI.




Figure 4: A direct correlation between LDL level and the aorta diameter. Furthermore, an opposite correlation between the left ventricle (LV) diastolic size and the EF.

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5) MD pairwise deleted Marked correlations are significant at p < .05000		
	Date of infarct	Date of hosp.	Date of dischagement
	1,000000	<b>0,998755</b>	<b>0,998662</b>
Date of hosp.	<b>0,998755</b>	1,000000	<b>0,999754</b>
Date of dischagement	<b>0,998662</b>	<b>0,999754</b>	1,000000
Hospitalization days	<b>-0,492819</b>	<b>-0,480996</b>	<b>-0,470104</b>
Age	-0,014406	-0,017981	-0,017534
Body weight	-0,042648	-0,056196	-0,057004
Height	-0,171595	-0,175662	-0,173637
BMI	-0,050015	-0,060710	-0,063937
HR	-0,026789	-0,029367	-0,028830
SBP	0,086786	0,096680	0,094712
DBP	0,050813	0,050794	0,050194
Aorta diameter at the Valsalva sinuses (mm)	-0,029993	-0,022536	-0,025733
EF (%)	0,080422	0,083670	0,083384
EDV (ml)	-0,045009	-0,050675	-0,052638
End diastolic LV size (mm)	-0,001416	-0,023427	-0,022092
End diastolic LA size (mm)	0,123265	0,117261	0,118687
End diastolic RV size (mm)	<b>0,224438</b>	<b>0,209813</b>	<b>0,208153</b>
End diastolic RA size (mm)	0,130204	0,133860	0,135790
Hb	0,037855	0,024145	0,023418
leukocytes	0,142190	0,118443	0,118092
RBC	0,013550	-0,027649	-0,029574
lymphocytes	0,091797	0,095098	0,093676
Thrombocytes	<b>-0,210074</b>	<b>-0,213754</b>	<b>-0,213379</b>
ESR	-0,014440	-0,027477	-0,027431
Ketones			
Urine proteins	<b>0,302814</b>	<b>0,302253</b>	<b>0,305086</b>
leukocytes	<b>-0,344187</b>	<b>-0,325607</b>	<b>-0,325124</b>
epithelial cells	<b>-0,404424</b>	<b>-0,392751</b>	<b>-0,392272</b>
Troponin I	-0,082746	-0,087620	-0,089514
Myoglobin	0,500000	0,500000	0,500000
CKP-MB 1	-0,161461	-0,146670	-0,146545
CKP-MB 2	<b>-0,369494</b>	<b>-0,367680</b>	<b>-0,369441</b>
LDH 1	0,030811	0,026900	0,027219
LDH 2	0,123665	0,119836	0,113804
INR	<b>0,222657</b>	<b>0,210509</b>	<b>0,210587</b>
Total bilirubin	-0,070080	-0,093753	-0,091667
ALT	-0,025792	-0,033286	-0,036998
AST	0,033419	0,045471	0,045172
Total choles	-0,081606	-0,083591	-0,082453
LDL	-0,120629	-0,114472	-0,110837
TAG	0,075539	0,041802	0,040081
Na	<b>0,295534</b>	<b>0,320231</b>	<b>0,323290</b>
K	<b>0,392714</b>	<b>0,347683</b>	<b>0,345315</b>
Creatinine	-0,123623	-0,108991	-0,107730
Ca	<b>0,752734</b>	<b>0,655580</b>	<b>0,652954</b>

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5) MD pairwise deleted Marked correlations are significant at p <,05000			
	Date of infarct	Date of hosp.	Date of dischagement	
Uria	<b>0,173533</b>	<b>0,172153</b>		<b>0,172156</b>
Glucose	<b>0,198889</b>	<b>0,197077</b>		<b>0,199063</b>
APTT	-0,219685	-0,213583		-0,214560
Fibrinogen	0,070849	0,061743		0,060104
PT				

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5) MD pairwise deleted Marked correlations are significant at p <,05000			
	Hospitalization days	Age	Body weight	Height
Date of infarct	<b>-0,492819</b>	-0,014406	-0,042648	-0,171595
Date of hosp.	<b>-0,480996</b>	-0,017981	-0,056196	-0,175662
Date of dischagement	<b>-0,470104</b>	-0,017534	-0,057004	-0,173637
Hospitalization days	1,000000	0,092495	-0,239856	0,084892
Age	0,092495	1,000000	-0,056415	0,005208
Body weight	-0,239856	-0,056415	1,000000	-0,178452
Height	0,084892	0,005208	-0,178452	1,000000
BMI	-0,336077	0,029871	<b>0,898731</b>	<b>-0,536541</b>
HR	0,045764	-0,060908	<b>0,438935</b>	-0,249103
SBP	-0,063265	-0,054161	0,136715	-0,045358
DBP	0,004338	-0,110726	0,041841	-0,011282
Aorta diameter at the Valsalva sinuses (mm)	-0,056556	-0,058935	-0,108477	0,305970
EF (%)	-0,041657	-0,145918	-0,120649	-0,248037
EDV (ml)	-0,066685	-0,098928	0,438158	0,294385
End diastolic LV size (mm)	0,021873	-0,076707	0,348287	0,273553
End diastolic LA size (mm)	-0,006042	<b>0,177610</b>	0,177460	0,185164
End diastolic RV size (mm)	-0,087129	0,037892	<b>0,415737</b>	-0,152526
End diastolic RA size (mm)	-0,018941	0,161934	0,180343	0,397011
Hb	-0,162796	-0,157068	0,085367	0,176164
leukocytes	0,078156	-0,021030	-0,100778	-0,041827
RBC	<b>-0,185504</b>	<b>-0,230622</b>	0,050290	0,136868
lymphocytes	<b>-0,187678</b>	-0,150462	-0,124957	-0,175052
Thrombocytes	-0,053971	-0,000641	0,182193	-0,059169
ESR	0,026856	<b>0,200394</b>	-0,132872	-0,297634
Ketones				
Urine proteins	-0,030714	-0,031736	-0,234565	0,200668
leukocytes	<b>0,220460</b>	0,072826	0,111436	-0,010736
epithelial cells	<b>0,251582</b>	0,047546	0,069070	0,060775
Troponin I	0,036854	0,170201	0,307384	0,038983
Myoglobin	-0,500000			
CKP-MB 1	0,062096	0,120242	0,221078	0,154298
CKP-MB 2	-0,060476	0,003794	-0,462185	<b>0,692409</b>
LDH 1	0,075959	0,172099	0,461451	0,083129
LDH 2	<b>-0,351822</b>	-0,035860	-0,342356	<b>0,882919</b>
INR	-0,122041	0,088783	-0,087567	-0,115722

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)			
	MD pairwise deleted			
	Marked correlations are significant at p <,05000			
	Hospitalization days	Age	Body weight	Height
Total bilirubin	0,083439	0,119390	0,142107	0,304978
ALT	-0,149559	0,006031	0,357989	-0,136986
AST	-0,089148	0,053983	0,255829	0,051121
Total choles	0,135370	0,189818	0,032294	-0,138274
LDL	0,159497	0,103719	0,214156	-0,089237
TAG	-0,018082	-0,089894	0,190830	-0,346317
Na	-0,074054	0,042710	0,099801	-0,086951
K	-0,119386	0,096715	0,262988	-0,486864
Creatinine	0,118681	0,196371	-0,007508	0,035929
Ca	-0,365114	-0,006410	0,283974	-0,338311
Uria	-0,032561	0,189761	0,121533	-0,404216
Glucose	-0,002611	0,166185	0,654202	-0,048985
APTT	0,142006	0,049935	0,003153	-0,204839
Fibrinogen	0,014194	-0,101096	-0,200220	-0,219706
PT				

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	BMI	HR	SBP	DBP	Aorta diameter
Date of infarct	-0,050015	-0,026789	0,086786	0,050813	-0,029993
Date of hosp.	-0,060710	-0,029367	0,096680	0,050794	-0,022536
Date of dischargement	-0,063937	-0,028830	0,094712	0,050194	-0,025733
Hospitalization days	-0,336077	0,045764	-0,063265	0,004338	-0,056556
Age	0,029871	-0,060908	-0,054161	-0,110726	-0,058935
Body weight	0,898731	0,438935	0,136715	0,041841	-0,108477
Height	-0,536541	-0,249103	-0,045358	-0,011282	0,305970
BMI	1,000000	0,475827	0,233983	0,134203	-0,303926
HR	0,475827	1,000000	0,164042	0,193671	0,056941
SBP	0,233983	0,164042	1,000000	0,837480	0,062520
DBP	0,134203	0,193671	0,837480	1,000000	0,109910
Aorta diameter at the Valsalva sinuses (mm)	-0,303926	0,056941	0,062520	0,109910	1,000000
EF (%)	-0,032926	-0,178774	0,093906	0,042189	0,050386
EDV (ml)	0,321078	0,012821	0,129426	0,181506	0,126137
End diastolic LV size (mm)	0,062654	0,108568	0,078351	0,214669	0,217956
End diastolic LA size (mm)	-0,090691	-0,033390	0,127778	0,117089	0,220792
End diastolic RV size (mm)	0,343756	0,122876	0,107076	0,187414	0,339438
End diastolic RA size (mm)	-0,040683	0,009769	-0,000967	0,056850	0,222980
Hb	0,065826	0,031176	0,017701	0,064565	0,077202
leukocytes	-0,091010	-0,047458	-0,010262	0,043619	-0,101208
RBC	0,131963	-0,109265	0,008063	0,010929	-0,012348
lymphocytes	0,044404	0,126764	-0,023606	0,000627	0,038371
Thrombocytes	0,253130	0,129454	-0,104800	-0,053676	-0,208526
ESR	-0,000494	0,084674	-0,118841	-0,048738	-0,041583
Ketones					
Urine proteins	-0,238145	-0,171914	0,073485	0,051278	-0,084270

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	BMI	HR	SBP	DBP	Aorta diameter
leukocytes	0,186406	-0,010679	0,051028	-0,026506	<b>-0,196673</b>
epithelial cells	0,114878	0,018641	0,042596	-0,026188	-0,137258
Troponin I	0,335063	-0,054693	<b>-0,195500</b>	<b>-0,180407</b>	-0,105639
Myoglobulin		1,000000	1,000000	0,866025	
CKP-MB 1	0,102362	0,072393	-0,149235	-0,148068	-0,134453
CKP-MB 2	-0,543938	0,019912	-0,021319	0,048399	0,081346
LDH 1	0,437790	-0,043696	<b>-0,196905</b>	<b>-0,227802</b>	<b>-0,317959</b>
LDH 2	-0,357143	-0,065697	-0,047346	-0,023404	-0,025929
INR	0,016422	-0,176321	-0,009411	-0,032399	0,012770
Total bilirubin Rubin	0,013691	0,091752	-0,074120	-0,152479	0,105600
ALT	<b>0,462577</b>	<b>0,168135</b>	-0,014180	-0,079591	-0,081878
AST	0,191586	0,058756	-0,161133	-0,161825	0,016592
Total choles	0,167920	0,074696	0,130019	0,103124	<b>-0,272978</b>
LDL	0,287161	-0,019979	0,048523	0,051746	<b>-0,290000</b>
TAG	0,243163	-0,001737	0,159888	<b>0,203202</b>	-0,064514
Na	0,147481	0,017900	0,073128	0,023359	0,012202
K	<b>0,402687</b>	0,055393	0,000735	-0,018963	0,099267
Creatinine	-0,051752	-0,018731	-0,115542	<b>-0,229538</b>	-0,130249
Ca	<b>0,422982</b>	-0,077756	-0,065510	-0,085972	-0,005432
Uria	0,221784	0,076878	-0,020419	-0,078703	-0,032316
Glucose	<b>0,497591</b>	0,077596	-0,030442	-0,022622	0,053932
APTT	0,145463	0,034608	-0,055021	-0,086966	-0,118503
Fibrinogen	-0,051268	-0,068684	0,014181	-0,081389	-0,066697
PT					

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)					
	MD pairwise deleted					
	Marked correlations are significant at p <,05000					
	EF	EDV	LV	LA	RV	RA
Date of infarct	0,080422	-0,045009	-0,001416	0,123265	<b>0,224438</b>	0,130204
Date of hosp.	0,083670	-0,050675	-0,023427	0,117261	<b>0,209813</b>	0,133860
Date of dischargement	0,083384	-0,052638	-0,022092	0,118687	<b>0,208153</b>	0,135790
Hospitalization days	-0,041657	-0,066685	0,021873	-0,006042	-0,087129	-0,018941
Age	-0,145918	-0,098928	-0,076707	<b>0,177610</b>	0,037892	0,161934
Body weight	-0,120649	0,438158	0,348287	0,177460	<b>0,415737</b>	0,180343
Height	-0,248037	0,294385	0,273553	0,185164	-0,152526	0,397011
BMI	-0,032926	0,321078	0,062654	-0,090691	0,343756	-0,040683
HR	<b>-0,178774</b>	0,012821	0,108568	-0,033390	0,122876	0,009769
SBP	0,093906	0,129426	0,078351	0,127778	0,107076	-0,000967
DBP	0,042189	0,181506	<b>0,214669</b>	0,117089	<b>0,187414</b>	0,056850
Aorta diameter	0,050386	0,126137	<b>0,217956</b>	<b>0,220792</b>	<b>0,339438</b>	<b>0,222980</b>
EF	1,000000	<b>-0,204007</b>	<b>-0,306233</b>	-0,037623	0,037063	0,051806
EDV	<b>-0,204007</b>	1,000000	<b>0,816552</b>	<b>0,427731</b>	<b>0,232208</b>	0,153922
LV	<b>-0,306233</b>	<b>0,816552</b>	1,000000	<b>0,373137</b>	<b>0,198793</b>	<b>0,180908</b>
LA	-0,037623	<b>0,427731</b>	<b>0,373137</b>	1,000000	<b>0,421956</b>	<b>0,553528</b>
RV	0,037063	<b>0,232208</b>	<b>0,198793</b>	<b>0,421956</b>	1,000000	<b>0,222865</b>
RA	0,051806	0,153922	<b>0,180908</b>	<b>0,553528</b>	<b>0,222865</b>	1,000000
Hb	0,022881	0,107920	0,016682	0,074045	0,114354	0,011420
leukocytes	<b>-0,181839</b>	<b>0,209526</b>	0,089332	0,077030	0,139811	-0,037217
RBC	0,070459	0,014637	0,022377	-0,065412	0,136926	-0,022704
lymphocytes	0,019908	-0,086165	-0,038685	-0,084508	-0,061272	-0,150101
Thrombocytes	-0,007202	0,042597	-0,055031	-0,195668	-0,085269	-0,108218
ESR	-0,008205	0,068129	0,064889	-0,004561	-0,030127	0,084620

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)					
	MD pairwise deleted					
	Marked correlations are significant at p <,05000					
	EF	EDV	LV	LA	RV	RA
Ketones						
Urine proteins	0,162382	-0,145296	-0,080618	-0,139515	-0,001364	0,111536
leukocytes	-0,102500	0,026230	-0,042291	0,040654	-0,106300	-0,140144
epithelial cells	-0,153045	-0,042611	-0,066126	-0,099064	<b>-0,243669</b>	<b>-0,234743</b>
Troponin I	-0,053490	-0,054769	-0,119882	-0,106785	-0,094003	-0,032516
Myoglobin	1,000000			-0,500000		
CKP-MB 1	-0,059120	0,042945	-0,080071	-0,114084	<b>-0,232948</b>	-0,029421
CKP-MB 2	-0,037202	-0,058452	-0,086273	0,007858	-0,009298	0,032700
LDH 1	-0,121081	0,078570	-0,081344	-0,087928	-0,057713	-0,049061
LDH 2	-0,131816	-0,114369	-0,150290	-0,053576	-0,082071	0,011156
INR	-0,041426	0,021536	-0,046075	0,055728	0,098168	0,162673
Total bilirubin Rubin	-0,161993	0,154520	0,007623	0,182757	<b>0,195401</b>	0,054035
ALT	-0,068176	0,069499	0,009479	0,064334	0,083873	0,022768
AST	-0,100612	0,069440	0,068600	-0,049618	0,001424	0,077034
Total choles	0,001418	-0,010848	-0,034502	-0,022993	-0,008355	-0,160652
LDL	-0,003403	-0,023996	-0,070730	-0,008003	0,006907	-0,091096
TAG	0,135686	-0,012581	0,085614	0,071785	0,096231	-0,036389
Na	0,028201	-0,062749	0,045815	0,144556	-0,055881	0,181103
K	0,047078	0,058684	-0,002292	0,117294	<b>0,285462</b>	0,147145
Creatinine	-0,136330	-0,094480	-0,066634	-0,027856	<b>-0,207834</b>	-0,101998
Ca	0,020465	-0,047146	-0,021513	<b>0,265162</b>	0,180772	0,166642
Uria	0,005515	-0,078861	-0,037700	<b>0,189547</b>	<b>0,194250</b>	0,101188
Glucose	-0,146818	0,043452	0,129861	0,175194	<b>0,223505</b>	0,171877
APTT	-0,201638	0,173079	0,040094	-0,129817	-0,000931	-0,139865
Fibrinogen	0,067573	-0,119314	-0,116229	0,006765	-0,007770	-0,072335
PT						

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	Hb	leukocytes	RBC	lymphocytes	Thrombocytes
Date of infarct	0,037855	0,142190	0,013550	0,091797	<b>-0,210074</b>
Date of hosp.	0,024145	0,118443	-0,027649	0,095098	<b>-0,213754</b>
Date of dischargement	0,023418	0,118092	-0,029574	0,093676	<b>-0,213379</b>
Hospitalization days	-0,162796	0,078156	<b>-0,185504</b>	<b>-0,187678</b>	-0,053971
Age	-0,157068	-0,021030	<b>-0,230622</b>	-0,150462	-0,000641
Body weight	0,085367	-0,100778	0,050290	-0,124957	0,182193
Height	0,176164	-0,041827	0,136868	-0,175052	-0,059169
BMI	0,065826	-0,091010	0,131963	0,044404	0,253130
HR	0,031176	-0,047458	-0,109265	0,126764	0,129454
SBP	0,017701	-0,010262	0,008063	-0,023606	-0,104800
DBP	0,064565	0,043619	0,010929	0,000627	-0,053676
Aorta diameter	0,077202	-0,101208	-0,012348	0,038371	<b>-0,208526</b>
EF	0,022881	<b>-0,181839</b>	0,070459	0,019908	-0,007202
EDV	0,107920	<b>0,209526</b>	0,014637	-0,086165	0,042597
LV	0,016682	0,089332	0,022377	-0,038685	-0,055031
LA	0,074045	0,077030	-0,065412	-0,084508	-0,195668
RV	0,114354	0,139811	0,136926	-0,061272	-0,085269
RA	0,011420	-0,037217	-0,022704	-0,150101	-0,108218
Hb	1,000000	<b>0,268726</b>	<b>0,654935</b>	0,087015	0,058451
leukocytes	<b>0,268726</b>	1,000000	0,109458	<b>-0,407888</b>	<b>0,278365</b>
RBC	<b>0,654935</b>	0,109458	1,000000	0,111199	0,164037
lymphocytes	0,087015	<b>-0,407888</b>	0,111199	1,000000	-0,163473

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	Hb	leukocytes	RBC	lymphocytes	Thrombocytes
Thrombocytes	0,058451	<b>0,278365</b>	0,164037	-0,163473	1,000000
ESR	<b>-0,424196</b>	-0,053640	<b>-0,344304</b>	0,087865	0,071924
Ketones					
Urine proteins	<b>-0,194071</b>	0,143997	0,042784	<b>-0,208550</b>	-0,053757
leukocytes	-0,141955	0,072283	-0,037207	-0,139760	0,175763
epithelial cells	-0,036518	0,088763	-0,007425	-0,058215	0,092318
Troponin I	<b>0,228199</b>	<b>0,273322</b>	0,188032	-0,034776	<b>0,242812</b>
Myoglobin	-0,500000	1,000000		0,500000	
CKP-MB 1	0,046591	0,118350	-0,082001	0,063300	0,164946
CKP-MB 2	0,116045	0,071282	-0,021656	-0,153597	0,205310
LDH 1	-0,070553	<b>0,252933</b>	0,001593	-0,061029	0,095874
LDH 2	0,254468	<b>0,286870</b>	0,126967	-0,211282	<b>0,349153</b>
INR	0,101077	<b>0,187285</b>	0,052727	<b>-0,213453</b>	<b>0,200752</b>
Total bilirubin Rubin	<b>0,215681</b>	-0,040948	0,089829	0,074228	<b>-0,220295</b>
ALT	0,011558	0,067994	0,073779	-0,006331	0,035331
AST	-0,009187	0,072187	-0,080989	-0,038706	-0,083374
Total choles	0,066861	-0,025760	0,023385	0,111800	-0,011878
LDL	0,114681	-0,024549	0,091089	0,066237	0,051375
TAG	0,157777	<b>0,203652</b>	0,172810	0,157562	-0,017568
Na	0,081063	-0,068359	-0,027294	0,157465	-0,155198
K	<b>0,218370</b>	0,047010	0,187586	<b>0,193137</b>	-0,172012
Creatinine	-0,024685	0,068294	-0,137145	-0,124911	0,183592
Ca	<b>0,194971</b>	0,060749	<b>0,269192</b>	<b>0,198846</b>	-0,046922
Uria	<b>-0,211940</b>	0,037870	-0,139107	-0,165130	-0,004645
Glucose	-0,008374	<b>0,205235</b>	0,090559	-0,125482	-0,062960
APTT	0,102761	0,104666	0,174735	0,011001	<b>0,316938</b>
Fibrinogen	-0,051919	-0,093511	0,020243	0,044111	<b>-0,224921</b>
PT					

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	ESR	Ketones	Urine proteins	leukocytes	epithelial cells
Date of infarct	-0,014440		<b>0,302814</b>	<b>-0,344187</b>	<b>-0,404424</b>
Date of hosp.	-0,027477		<b>0,302253</b>	<b>-0,325607</b>	<b>-0,392751</b>
Date of dischargement	-0,027431		<b>0,305086</b>	<b>-0,325124</b>	<b>-0,392272</b>
Hospitalization days	0,026856		-0,030714	<b>0,220460</b>	<b>0,251582</b>
Age	<b>0,200394</b>		-0,031736	0,072826	0,047546
Body weight	-0,132872		-0,234565	0,111436	0,069070
Height	-0,297634		0,200668	-0,010736	0,060775
BMI	-0,000494		-0,238145	0,186406	0,114878
HR	0,084674		<b>-0,171914</b>	-0,010679	0,018641
SBP	-0,118841		0,073485	0,051028	0,042596
DBP	-0,048738		0,051278	-0,026506	-0,026188
Aorta diameter	-0,041583		-0,084270	<b>-0,196673</b>	-0,137258
EF	-0,008205		0,162382	-0,102500	-0,153045
EDV	0,068129		-0,145296	0,026230	-0,042611
LV	0,064889		-0,080618	-0,042291	-0,066126
LA	-0,004561		-0,139515	0,040654	-0,099064
RV	-0,030127		-0,001364	-0,106300	<b>-0,243669</b>
RA	0,084620		0,111536	-0,140144	<b>-0,234743</b>
Hb	<b>-0,424196</b>		<b>-0,194071</b>	-0,141955	-0,036518
leukocytes	-0,053640		0,143997	0,072283	0,088763

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	ESR	Ketones	Urine proteins	leukocytes	epithelial cells
RBC	-0,344304		0,042784	-0,037207	-0,007425
lymphocytes	0,087865		-0,208550	-0,139760	-0,058215
Thrombocytes	0,071924		-0,053757	0,175763	0,092318
ESR	1,000000		-0,031909	-0,021033	-0,089231
Ketones		1,000000			
Urine proteins	-0,031909		1,000000	0,037846	-0,035824
leukocytes	-0,021033		0,037846	1,000000	0,789820
epithelial cells	-0,089231		-0,035824	0,789820	1,000000
Troponin I	-0,039481		0,045506	0,071426	0,106241
Myoglobin	0,500000		0,866025	0,500000	0,500000
CKP-MB 1	0,098663		-0,044192	0,172589	0,239036
CKP-MB 2	0,013043		-0,291265	0,219115	0,329329
LDH 1	0,047350		0,137175	0,128269	0,040671
LDH 2	-0,210693		0,046534	-0,120852	-0,084567
INR	-0,019873		0,145399	-0,010482	-0,113416
Total bilirubin Rubin	-0,048101		0,032055	-0,140302	-0,083612
ALT	0,013972		-0,037007	-0,097826	-0,028856
AST	0,000510		0,091987	-0,132582	-0,041266
Total choles	-0,128001		-0,061160	0,106976	0,121417
LDL	-0,102900		-0,057283	0,212155	0,184569
TAG	0,038587		0,007271	-0,001248	0,020937
Na	-0,101750		-0,070218	-0,177667	-0,162685
K	-0,033521		-0,049361	-0,202077	-0,275099
Creatinine	-0,097531		0,030465	0,177259	0,158177
Ca	-0,090898		0,007566	-0,376993	-0,433478
Uria	0,165846		0,190483	0,099496	0,036004
Glucose	0,021904		0,109950	0,067847	0,160787
APTT	-0,032073		-0,184248	0,223590	0,313909
Fibrinogen	-0,019113		0,032734	0,074379	0,100294
PT					

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	Troponin I	Myoglobin	CKP-MB 1	CKP-MB 2	LDH 1
Date of infarct	-0,082746	0,50000	-0,161461	-0,369494	0,030811
Date of hosp.	-0,087620	0,50000	-0,146670	-0,367680	0,026900
Date of dischargement	-0,089514	0,50000	-0,146545	-0,369441	0,027219
Hospitalization days	0,036854	-0,50000	0,062096	-0,060476	0,075959
Age	0,170201		0,120242	0,003794	0,172099
Body weight	0,307384		0,221078	-0,462185	0,461451
Height	0,038983		0,154298	0,692409	0,083129
BMI	0,335063		0,102362	-0,543938	0,437790
HR	-0,054693	1,00000	0,072393	0,019912	-0,043696
SBP	-0,195500	1,00000	-0,149235	-0,021319	-0,196905
DBP	-0,180407	0,86603	-0,148068	0,048399	-0,227802
Aorta diameter	-0,105639		-0,134453	0,081346	-0,317959
EF	-0,053490	1,00000	-0,059120	-0,037202	-0,121081
EDV	-0,054769		0,042945	-0,058452	0,078570
LV	-0,119882		-0,080071	-0,086273	-0,081344
LA	-0,106785	-0,50000	-0,114084	0,007858	-0,087928
RV	-0,094003		-0,232948	-0,009298	-0,057713
RA	-0,032516		-0,029421	0,032700	-0,049061

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	Troponin I	Myoglobulin	CKP-MB 1	CKP-MB 2	LDH 1
Hb	<b>0,228199</b>	-0,50000	0,046591	0,116045	-0,070553
leukocytes	<b>0,273322</b>	1,00000	0,118350	0,071282	<b>0,252933</b>
RBC	0,188032		-0,082001	-0,021656	0,001593
lymphocytes	-0,034776	0,50000	0,063300	-0,153597	-0,061029
Thrombocytes	<b>0,242812</b>		0,164946	0,205310	0,095874
ESR	-0,039481	0,50000	0,098663	0,013043	0,047350
Ketones					
Urine proteins	0,045506	0,86603	-0,044192	<b>-0,291265</b>	0,137175
leukocytes	0,071426	0,50000	0,172589	0,219115	0,128269
epithelial cells	0,106241	0,50000	<b>0,239036</b>	<b>0,329329</b>	0,040671
Troponin I	1,000000		<b>0,490390</b>	<b>0,265996</b>	<b>0,374820</b>
Myoglobulin		1,00000			
CKP-MB 1	<b>0,490390</b>		1,000000	<b>0,386079</b>	<b>0,576087</b>
CKP-MB 2	<b>0,265996</b>		<b>0,386079</b>	1,000000	0,067851
LDH 1	<b>0,374820</b>		<b>0,576087</b>	0,067851	1,000000
LDH 2	<b>0,319420</b>		0,127235	<b>0,437527</b>	<b>0,314912</b>
INR	<b>0,208372</b>		0,057017	0,000653	0,141873
Total bilirubin	0,166543		0,189142	0,018849	0,112833
ALT	0,130182		0,152500	0,057059	<b>0,200843</b>
AST	0,170510		<b>0,194561</b>	0,053218	<b>0,241813</b>
Total choles	0,124187	0,50000	-0,040978	-0,006981	0,082099
LDL	<b>0,195942</b>	0,50000	0,061061	0,116077	0,097868
TAG	0,075288	0,50000	-0,001916	-0,046766	0,003054
Na	0,073038	-1,00000	-0,145310	-0,202524	0,056657
K	0,111597	0,50000	0,007184	-0,162865	0,162139
Creatinine	<b>0,177284</b>	-1,00000	<b>0,260587</b>	-0,008614	<b>0,226690</b>
Ca	0,002295		<b>-0,255494</b>	<b>-0,448271</b>	-0,032190
Uria	0,077832	0,50000	0,050858	-0,208204	0,114875
Glucose	-0,027007	1,00000	-0,062950	-0,082192	0,112243
APTT	0,126145		<b>0,309909</b>	<b>0,423780</b>	0,087702
Fibrinogen	-0,126763		0,019966	-0,141352	0,038093
PT					

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	LDH 2	INR	Total bilirubin	ALT	AST
Date of infarct	0,123665	<b>0,222657</b>	-0,070080	-0,025792	0,033419
Date of hosp.	0,119836	<b>0,210509</b>	-0,093753	-0,033286	0,045471
Date of dischargement	0,113804	<b>0,210587</b>	-0,091667	-0,036998	0,045172
Hospitalization days	<b>-0,351822</b>	-0,122041	0,083439	-0,149559	-0,089148
Age	-0,035860	0,088783	0,119390	0,006031	0,053983
Body weight	-0,342356	-0,087567	0,142107	0,357989	0,255829
Height	<b>0,882919</b>	-0,115722	0,304978	-0,136986	0,051121
BMI	-0,357143	0,016422	0,013691	<b>0,462577</b>	0,191586
HR	-0,065697	-0,176321	0,091752	<b>0,168135</b>	0,058756
SBP	-0,047346	-0,009411	-0,074120	-0,014180	-0,161133
DBP	-0,023404	-0,032399	-0,152479	-0,079591	-0,161825
Aorta diameter	-0,025929	0,012770	0,105600	-0,081878	0,016592
EF	-0,131816	-0,041426	-0,161993	-0,068176	-0,100612
EDV	-0,114369	0,021536	0,154520	0,069499	0,069440
LV	-0,150290	-0,046075	0,007623	0,009479	0,068600

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5) MD pairwise deleted Marked correlations are significant at p <,05000				
	LDH 2	INR	Total bilirubin	ALT	AST
	-0,053576	0,055728	0,182757	0,064334	-0,049618
LA	-0,082071	0,098168	0,195401	0,083873	0,001424
RA	0,011156	0,162673	0,054035	0,022768	0,077034
Hb	0,254468	0,101077	0,215681	0,011558	-0,009187
leukocytes	0,286870	0,187285	-0,040948	0,067994	0,072187
RBC	0,126967	0,052727	0,089829	0,073779	-0,080989
lymphocytes	-0,211282	-0,213453	0,074228	-0,006331	-0,038706
Thrombocytes	0,349153	0,200752	-0,220295	0,035331	-0,083374
ESR	-0,210693	-0,019873	-0,048101	0,013972	0,000510
Ketones					
Urine proteins	0,046534	0,145399	0,032055	-0,037007	0,091987
leukocytes	-0,120852	-0,010482	-0,140302	-0,097826	-0,132582
epithelial cells	-0,084567	-0,113416	-0,083612	-0,028856	-0,041266
Troponin I	0,319420	0,208372	0,166543	0,130182	0,170510
Myoglobulin					
CKP-MB 1	0,127235	0,057017	0,189142	0,152500	0,194561
CKP-MB 2	0,437527	0,000653	0,018849	0,057059	0,053218
LDH 1	0,314912	0,141873	0,112833	0,200843	0,241813
LDH 2	1,000000	0,382124	0,002090	0,286460	0,447358
INR	0,382124	1,000000	0,107299	-0,044216	0,049075
Total bilirubin	0,002090	0,107299	1,000000	0,175968	0,135787
ALT	0,286460	-0,044216	0,175968	1,000000	0,572879
AST	0,447358	0,049075	0,135787	0,572879	1,000000
Total choles	-0,049465	-0,111364	0,135346	0,068525	0,067669
LDL	-0,043774	-0,011290	0,158629	0,020542	0,064199
TAG	-0,033778	-0,095456	-0,039331	0,126804	0,040082
Na	0,126636	0,138965	-0,085883	-0,015813	0,130889
K	-0,091874	0,175417	0,134458	0,035404	0,062157
Creatinine	-0,170041	0,185665	0,069496	-0,021837	0,002576
Ca	-0,065550	0,229418	-0,076928	0,098510	-0,040195
Uria	-0,156195	0,132454	0,048647	0,248900	0,155723
Glucose	0,089111	0,031761	-0,009808	0,246838	0,156518
APTT	0,197419	0,167639	0,073983	0,084182	-0,016993
Fibrinogen	-0,089828	-0,389201	0,105851	-0,003601	-0,044486
PT					

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5) MD pairwise deleted Marked correlations are significant at p <,05000				
	Total choles	LDL	TAG	Na	K
	-0,081606	-0,120629	0,075539	0,29553	0,392714
Date of infarct	-0,083591	-0,114472	0,041802	0,32023	0,347683
Date of hosp.	-0,082453	-0,110837	0,040081	0,32329	0,345315
Date of dischargement	0,135370	0,159497	-0,018082	-0,07405	-0,119386
Hospitalization days	0,189818	0,103719	-0,089894	0,04271	0,096715
Age	0,032294	0,214156	0,190830	0,09980	0,262988
Body weight	-0,138274	-0,089237	-0,346317	-0,08695	-0,486864
Height	0,167920	0,287161	0,243163	0,14748	0,402687
BMI	0,074696	-0,019979	-0,001737	0,01790	0,055393
HR	0,130019	0,048523	0,159888	0,07313	0,000735
SBP	0,103124	0,051746	0,203202	0,02336	-0,018963
DBP	-0,272978	-0,290000	-0,064514	0,01220	0,099267
Aorta diameter					

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	Total choles	LDL	TAG	Na	K
EF	0,001418	-0,003403	0,135686	0,02820	0,047078
EDV	-0,010848	-0,023996	-0,012581	-0,06275	0,058684
LV	-0,034502	-0,070730	0,085614	0,04582	-0,002292
LA	-0,022993	-0,008003	0,071785	0,14456	0,117294
RV	-0,008355	0,006907	0,096231	-0,05588	<b>0,285462</b>
RA	-0,160652	-0,091096	-0,036389	0,18110	0,147145
Hb	0,066861	0,114681	0,157777	0,08106	<b>0,218370</b>
leukocytes	-0,025760	-0,024549	<b>0,203652</b>	-0,06836	0,047010
RBC	0,023385	0,091089	0,172810	-0,02729	0,187586
lymphocytes	0,111800	0,066237	0,157562	0,15747	<b>0,193137</b>
Thrombocytes	-0,011878	0,051375	-0,017568	-0,15520	-0,172012
ESR	-0,128001	-0,102900	0,038587	-0,10175	-0,033521
Ketones					
Urine proteins	-0,061160	-0,057283	0,007271	-0,07022	-0,049361
leukocytes	0,106976	<b>0,212155</b>	-0,001248	-0,17767	<b>-0,202077</b>
epithelial cells	0,121417	<b>0,184569</b>	0,020937	-0,16269	<b>-0,275099</b>
Troponin I	0,124187	<b>0,195942</b>	0,075288	0,07304	0,111597
Myoglobin	0,500000	0,500000	0,500000	-1,00000	0,500000
CKP-MB 1	-0,040978	0,061061	-0,001916	-0,14531	0,007184
CKP-MB 2	-0,006981	0,116077	-0,046766	-0,20252	-0,162865
LDH 1	0,082099	0,097868	0,003054	0,05666	0,162139
LDH 2	-0,049465	-0,043774	-0,033778	0,12664	-0,091874
INR	-0,111364	-0,011290	-0,095456	0,13897	0,175417
Total bilirubin	0,135346	0,158629	-0,039331	-0,08588	0,134458
ALT	0,068525	0,020542	0,126804	-0,01581	0,035404
AST	0,067669	0,064199	0,040082	0,13089	0,062157
Total choles	1,000000	<b>0,830689</b>	<b>0,417038</b>	0,09591	-0,006258
LDL	<b>0,830689</b>	1,000000	<b>0,319855</b>	0,06534	-0,075583
TAG	<b>0,417038</b>	<b>0,319855</b>	1,000000	-0,00482	0,096150
Na	0,095906	0,065343	-0,004822	1,00000	<b>0,349223</b>
K	-0,006258	-0,075583	0,096150	<b>0,34922</b>	1,000000
Creatinine	0,083018	0,087098	-0,032333	-0,01335	-0,060077
Ca	-0,108344	-0,126906	0,066131	<b>0,47663</b>	<b>0,575797</b>
Uria	0,046621	0,055896	0,027175	0,09747	0,132856
Glucose	0,048354	0,026693	0,161067	-0,03075	0,004122
APTT	0,110501	0,148558	-0,068772	-0,11314	0,049147
Fibrinogen	0,044268	-0,029297	0,160949	-0,09123	0,017443
PT					

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	Creatinine	Ca	Uria	Glucose	APTT
Date of infarct	-0,12362	<b>0,752734</b>	<b>0,173533</b>	<b>0,198889</b>	-0,219685
Date of hosp.	-0,10899	<b>0,655580</b>	<b>0,172153</b>	<b>0,197077</b>	-0,213583
Date of dischargement	-0,10773	<b>0,652954</b>	<b>0,172156</b>	<b>0,199063</b>	-0,214560
Hospitalization days	0,11868	<b>-0,365114</b>	-0,032561	-0,002611	0,142006
Age	<b>0,19637</b>	-0,006410	<b>0,189761</b>	0,166185	0,049935
Body weight	-0,00751	0,283974	0,121533	<b>0,654202</b>	0,003153
Height	0,03593	-0,338311	<b>-0,404216</b>	-0,048985	-0,204839
BMI	-0,05175	<b>0,422982</b>	0,221784	<b>0,497591</b>	0,145463
HR	-0,01873	-0,077756	0,076878	0,077596	0,034608
SBP	-0,11554	-0,065510	-0,020419	-0,030442	-0,055021

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)				
	MD pairwise deleted				
	Marked correlations are significant at p <,05000				
	Creatinine	Ca	Uria	Glucose	APTT
DBP	<b>-0,22954</b>	-0,085972	-0,078703	-0,022622	-0,086966
Aorta diameter	-0,13025	-0,005432	-0,032316	0,053932	-0,118503
EF	-0,13633	0,020465	0,005515	-0,146818	-0,201638
EDV	-0,09448	-0,047146	-0,078861	0,043452	0,173079
LV	-0,06663	-0,021513	-0,037700	0,129861	0,040094
LA	-0,02786	<b>0,265162</b>	<b>0,189547</b>	0,175194	-0,129817
RV	<b>-0,20783</b>	0,180772	<b>0,194250</b>	<b>0,223505</b>	-0,000931
RA	-0,10200	0,166642	0,101188	0,171877	-0,139865
Hb	-0,02468	<b>0,194971</b>	<b>-0,211940</b>	-0,008374	0,102761
leukocytes	0,06829	0,060749	0,037870	<b>0,205235</b>	0,104666
RBC	-0,13715	<b>0,269192</b>	-0,139107	0,090559	0,174735
lymphocytes	-0,12491	<b>0,198846</b>	-0,165130	-0,125482	0,011001
Thrombocytes	0,18359	-0,046922	-0,004645	-0,062960	<b>0,316938</b>
ESR	-0,09753	-0,090898	0,165846	0,021904	-0,032073
Ketones					
Urine proteins	0,03047	0,007566	<b>0,190483</b>	0,109950	-0,184248
leukocytes	<b>0,17726</b>	<b>-0,376993</b>	0,099496	0,067847	0,223590
epithelial cells	0,15818	<b>-0,433478</b>	0,036004	0,160787	<b>0,313909</b>
Troponin I	<b>0,17728</b>	0,002295	0,077832	-0,027007	0,126145
Myoglobulin	-1,00000		0,500000	1,000000	
CKP-MB 1	<b>0,26059</b>	<b>-0,255494</b>	0,050858	-0,062950	<b>0,309909</b>
CKP-MB 2	-0,00861	<b>-0,448271</b>	-0,208204	-0,082192	<b>0,423780</b>
LDH 1	<b>0,22669</b>	-0,032190	0,114875	0,112243	0,087702
LDH 2	-0,17004	-0,065550	-0,156195	0,089111	0,197419
INR	<b>0,18567</b>	<b>0,229418</b>	0,132454	0,031761	0,167639
Total bilirubin	0,06950	-0,076928	0,048647	-0,009808	0,073983
ALT	-0,02184	0,098510	<b>0,248900</b>	<b>0,246838</b>	0,084182
AST	0,00258	-0,040195	0,155723	0,156518	-0,016993
Total choles	0,08302	-0,108344	0,046621	0,048354	0,110501
LDL	0,08710	-0,126906	0,055896	0,026693	0,148558
TAG	-0,03233	0,066131	0,027175	0,161067	-0,068772
Na	-0,01335	<b>0,476633</b>	0,097467	-0,030751	-0,113135
K	-0,06008	<b>0,575797</b>	0,132856	0,004122	0,049147
Creatinine	1,00000	-0,021655	<b>0,477372</b>	0,009566	0,130883
Ca	-0,02165	1,000000	<b>0,226440</b>	0,114659	-0,213578
Uria	<b>0,47737</b>	<b>0,226440</b>	1,000000	<b>0,223992</b>	-0,038725
Glucose	0,00957	0,114659	<b>0,223992</b>	1,000000	-0,091630
APTT	0,13088	-0,213578	-0,038725	-0,091630	1,000000
Fibrinogen	-0,03245	-0,074313	0,054461	0,016700	-0,101748
PT					

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5)	
	MD pairwise deleted	
	Marked correlations are significant at p <,05000	
	Fibrinogen	PT
Date of infarct	0,070849	
Date of hosp.	0,061743	
Date of dischargetment	0,060104	
Hospitalization days	0,014194	
Age	-0,101096	

Variable	Spearman Rank Order Correlations (Acute MI in Total Post MI 5) MD pairwise deleted Marked correlations are significant at p < ,05000	
	Fibrinogen	PT
Body weight	-0,200220	
Height	-0,219706	
BMI	-0,051268	
HR	-0,068684	
SBP	0,014181	
DBP	-0,081389	
Aorta diameter	-0,066697	
EF	0,067573	
EDV	-0,119314	
LV	-0,116229	
LA	0,006765	
RV	-0,007770	
RA	-0,072335	
Hb	-0,051919	
leukocytes	-0,093511	
RBC	0,020243	
lymphocytes	0,044111	
Thrombocytes	<b>-0,224921</b>	
ESR	-0,019113	
Ketones		
Urine proteins	0,032734	
leukocytes	0,074379	
epithelial cells	0,100294	
Troponin I	-0,126763	
Myoglobin		
CKP-MB 1	0,019966	
CKP-MB 2	-0,141352	
LDH 1	0,038093	
LDH 2	-0,089828	
INR	<b>-0,389201</b>	
Total bilirubin	0,105851	
ALT	-0,003601	
AST	-0,044486	
Total choles	0,044268	
LDL	-0,029297	
TAG	0,160949	
Na	-0,091235	
K	0,017443	
Creatinine	-0,032451	
Ca	-0,074313	
Uria	0,054461	
Glucose	0,016700	
APTT	-0,101748	
Fibrinogen	1,000000	
PT		1,000000

Variable	Correlations (Acute MI in Total Post MI 5) Marked correlations are significant at p $< ,05000$ N=30 (Case wise deletion of missing data) Body weight
BMI	<b>0,895885</b>